Nandini Kalakota

Dr. Nandini Kalakota

Hematology | Oncology
900 W Nelson St Ground Fl, 
Chicago, IL 
On Staff At
Offers Telehealth
900 W Nelson St Ground Fl, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nandini Kalakota is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Kalakota is rated as an Experienced provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of Illinois Medical Center, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
University of Illinois At Chicago, Hematology/Oncology
Hospital Affiliations
Advocate Illinois Masonic Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Advocate Medical Group Oncology
900 W Nelson St Ground Fl, Chicago, IL 60657

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
View 1 Less Clinical Trial

1 Total Publications

FOXM1 contributes to treatment failure in acute myeloid leukemia.
FOXM1 contributes to treatment failure in acute myeloid leukemia.
Journal: JCI insight
Published: April 12, 2018
Similar Doctors
Distinguished in Neuroendocrine Tumor
Dr. Mary F. Mulcahy
Hematology | Oncology
Distinguished in Neuroendocrine Tumor
Dr. Mary F. Mulcahy
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
866-587-4322
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Mulcahy is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mulcahy has been practicing medicine for over 33 years and is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.

Distinguished in Neuroendocrine Tumor
Dr. Halla S. Nimeiri
Hematology | Oncology
Distinguished in Neuroendocrine Tumor
Dr. Halla S. Nimeiri
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
866-587-4322
Experience:
34+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Halla Nimeiri is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Nimeiri has been practicing medicine for over 34 years and is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Liver Embolization.

Distinguished in Neuroendocrine Tumor
Dr. Sheetal M. Kircher
Hematology | Oncology
Distinguished in Neuroendocrine Tumor
Dr. Sheetal M. Kircher
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
866-587-4322
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sheetal Kircher is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Kircher has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Lynch Syndrome, and Liver Embolization.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kalakota's expertise for a condition
ConditionClose
        View All 48 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile